Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in I… Read more
Deciphera Pharmaceuticals Inc (D05) - Net Assets
Latest net assets as of March 2024: €316.05 Million EUR
Based on the latest financial reports, Deciphera Pharmaceuticals Inc (D05) has net assets worth €316.05 Million EUR as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€420.93 Million) and total liabilities (€104.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €316.05 Million |
| % of Total Assets | 75.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | -35.78% |
| 10-Year Change | N/A |
| Growth Volatility | 43.89 |
Deciphera Pharmaceuticals Inc - Net Assets Trend (2016–2023)
This chart illustrates how Deciphera Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Deciphera Pharmaceuticals Inc (2016–2023)
The table below shows the annual net assets of Deciphera Pharmaceuticals Inc from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €350.92 Million | +2.70% |
| 2022-12-31 | €341.69 Million | +12.13% |
| 2021-12-31 | €304.72 Million | -43.95% |
| 2020-12-31 | €543.68 Million | -0.51% |
| 2019-12-31 | €546.47 Million | +95.18% |
| 2018-12-31 | €279.98 Million | +52.19% |
| 2017-12-31 | €183.97 Million | +231.63% |
| 2016-12-31 | €-139.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Deciphera Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 128272000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.78 Billion | 507.02% |
| Total Equity | €350.92 Million | 100.00% |
Deciphera Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Deciphera Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MORGAN SINDALL GRP LS-05
F:0KN
|
$2.11 Billion |
|
Hui Lyu Ecological Technology Groups Co Ltd
SHE:001267
|
$2.11 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
$2.11 Billion |
|
Keda Clean Energy Co Ltd
SHG:600499
|
$2.11 Billion |
|
Oberbank AG
VI:OBS
|
$2.11 Billion |
|
OliX PharmaceuticalsInc
KQ:226950
|
$2.11 Billion |
|
Indra Sistemas S.A
OTCGREY:ISMAF
|
$2.11 Billion |
|
Sumitomo Rubber Industries Ltd
F:108
|
$2.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Deciphera Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 341,691,000 to 350,916,000, a change of 9,225,000 (2.7%).
- Net loss of 194,942,000 reduced equity.
- New share issuances of 149,747,000 increased equity.
- Other factors increased equity by 54,420,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-194.94 Million | -55.55% |
| Share Issuances | €149.75 Million | +42.67% |
| Other Changes | €54.42 Million | +15.51% |
| Total Change | €- | 2.70% |
Book Value vs Market Value Analysis
This analysis compares Deciphera Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 9.55x to 12.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.64 | €53.93 | x |
| 2018-12-31 | €7.43 | €53.93 | x |
| 2019-12-31 | €10.59 | €53.93 | x |
| 2020-12-31 | €9.44 | €53.93 | x |
| 2021-12-31 | €5.20 | €53.93 | x |
| 2022-12-31 | €5.05 | €53.93 | x |
| 2023-12-31 | €4.36 | €53.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Deciphera Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -119.34%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.35x
- Recent ROE (-55.55%) is below the historical average (-44.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | €-11.96 Million |
| 2017 | -27.33% | 0.00% | 0.00x | 1.08x | €-68.68 Million |
| 2018 | -35.66% | 0.00% | 0.00x | 1.13x | €-127.85 Million |
| 2019 | -35.18% | -769.02% | 0.04x | 1.14x | €-246.90 Million |
| 2020 | -49.02% | -633.19% | 0.07x | 1.18x | €-320.86 Million |
| 2021 | -98.44% | -311.98% | 0.22x | 1.41x | €-330.44 Million |
| 2022 | -52.37% | -133.49% | 0.30x | 1.33x | €-213.10 Million |
| 2023 | -55.55% | -119.34% | 0.34x | 1.35x | €-230.03 Million |
Industry Comparison
This section compares Deciphera Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,233,566,585
- Average return on equity (ROE) among peers: -96.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Deciphera Pharmaceuticals Inc (D05) | €316.05 Million | 0.00% | 0.33x | $2.11 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |